"Ursodeoxycholic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.
| Descriptor ID |
D014580
|
| MeSH Number(s) |
D04.210.500.105.225.272.962 D04.210.500.221.430.342.925
|
| Concept/Terms |
Ursodeoxycholic Acid- Ursodeoxycholic Acid
- Acid, Ursodeoxycholic
- Ursacholic Acid
- Acid, Ursacholic
- 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
- 3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid
- Ursodiol
- Deoxyursocholic Acid
- Acid, Deoxyursocholic
|
Below are MeSH descriptors whose meaning is more general than "Ursodeoxycholic Acid".
Below are MeSH descriptors whose meaning is more specific than "Ursodeoxycholic Acid".
This graph shows the total number of publications written about "Ursodeoxycholic Acid" by people in this website by year, and whether "Ursodeoxycholic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 4 | 4 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ursodeoxycholic Acid" by people in Profiles.
-
Primary biliary cholangitis. Lancet. 2024 Sep 14; 404(10457):1053-1066.
-
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):783-794.
-
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med. 2024 Feb 29; 390(9):795-805.
-
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 01; 59(2):186-200.
-
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023 08 01; 78(2):397-415.
-
Cholestasis impairs gut microbiota development and bile salt hydrolase activity in preterm neonates. Gut Microbes. 2023 Jan-Dec; 15(1):2183690.
-
Rolling stones: an instructive case of neonatal cholestasis. BMC Pediatr. 2022 09 04; 22(1):526.
-
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022 08; 77(2):353-364.
-
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021 06; 74(6):1344-1354.
-
Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 07; 66(7):2439-2451.